TITLE

Enumeration of CD4+ T-Cells Using a Portable Microchip Count Platform in Tanzanian HIV-Infected Patients

AUTHOR(S)
Moon, SangJun; Gurkan, Umut Atakan; Blander, Jeffrey; Fawzi, Wafaie W.; Aboud, Said; Mugusi, Ferdinand; Kuritzkes, Daniel R.; Demirci, Utkan
PUB. DATE
July 2011
SOURCE
PLoS ONE;2011, Vol. 6 Issue 7, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: CD4+ T-lymphocyte count (CD4 count) is a standard method used to monitor HIV-infected patients during anti-retroviral therapy (ART). The World Health Organization (WHO) has pointed out or recommended that a handheld, point-of-care, reliable, and affordable CD4 count platform is urgently needed in resource-scarce settings. Methods: HIV-infected patient blood samples were tested at the point-of-care using a portable and label-free microchip CD4 count platform that we have developed. A total of 130 HIV-infected patient samples were collected that included 16 de-identified left over blood samples from Brigham and Women's Hospital (BWH), and 114 left over samples from Muhimbili University of Health and Allied Sciences (MUHAS) enrolled in the HIV and AIDS care and treatment centers in the City of Dar es Salaam, Tanzania. The two data groups from BWH and MUHAS were analyzed and compared to the commonly accepted CD4 count reference method (FACSCalibur system). Results: The portable, battery operated and microscope-free microchip platform developed in our laboratory (BWH) showed significant correlation in CD4 counts compared with FACSCalibur system both at BWH (r = 0.94, p<0.01) and MUHAS (r = 0.49, p<0.01), which was supported by the Bland-Altman methods comparison analysis. The device rapidly produced CD4 count within 10 minutes using an in-house developed automated cell counting program. Conclusions: We obtained CD4 counts of HIV-infected patients using a portable platform which is an inexpensive (,$1 material cost) and disposable microchip that uses whole blood sample (<10 µl) without any pre-processing. The system operates without the need for antibody-based fluorescent labeling and expensive fluorescent illumination and microscope setup. This portable CD4 count platform displays agreement with the FACSCalibur results and has the potential to expand access to HIV and AIDS monitoring using fingerprick volume of whole blood and helping people who suffer from HIV and AIDS in resource-limited settings.
ACCESSION #
74548222

 

Related Articles

  • HIV guideline changes could slow virus spread.  // New Scientist;12/5/2009, Vol. 204 Issue 2737, p7 

    The article reports on the advice issued by the World Health Organization (WHO) to administer antiretroviral therapy (ART) to people with human immunodeficiency virus (HIV) earlier in the infection cycle. WHO suggests that ART be started when the levels of CD4 immune cells decreased below 200...

  • Antivirograma, sensible, rápido y fácil de interpretar por un método de bioluminiscencia para el VIH-1. Lara, H. H.; Ixtepan-Turrent, L.; Rivera-Silva, G.; González-Salazar, F.; Moreno-Treviño, G. // Revista Latinoamericana de Patología Clínica y Medicina de Lab;abr-jun2013, Vol. 60 Issue 2, p79 

    Objective: To demonstrate that our assay is sensitive capable to detect 10 HIV infected cells per well and that is feasible to quantify HIV-1 resistance in seropositive patients. Method: To compare 3 different phenotypic assays by quantifying their sensitivities, first we co-cultivated...

  • Persistence of HIV in Gut-associated Lymphoid Tissue with Antiretroviral Therapy. Winslow, Dean L. // Infectious Disease Alert;May2008, Vol. 27 Issue 8, p85 

    Eight HIV-infected patients (mean cd4+ T cell count 622 cells/uL) who had been receiving effective HAART for an average of 8.4 years were included in this study. PBMCs were obtained by leukapheresis and endoscopic terminal ileum biopsies were performed to obtain samples of Gut-Associated...

  • Early but limited effects of raltegravir intensification on CD4 T cell reconstitution in HIV-infected patients with an immunodiscordant response to antiretroviral therapy. Negredo, Eugènia; Massanella, Marta; Puertas, Maria C.; Buzón, Maria J.; Puig, Jordi; Pérez-Alvárez, Núria; Pérez-Santiago, Josué; Bonjoch, Anna; Moltó, José; Jou, Antoni; Echeverría, Patricia; Llibre, Josep M.; Martínez-Picado, Javier; Clotet, Bonaventura; Blanco, Julià // Journal of Antimicrobial Chemotherapy (JAC);Oct2013, Vol. 68 Issue 10, p2358 

    Background Immune hyperactivation in immunodiscordant patients can induce residual HIV replication and limit CD4 T cell recovery. We assessed the impact of raltegravir intensification on CD4 T cell recovery and viral persistence. Methods We performed a randomized, controlled, pilot trial....

  • Intestinal Parasitosis in Relation to Anti-Retroviral Therapy, CD4+ T-cell Count and Diarrhea in HIV Patients. Khalil, Shehla; Mirdha, Bijay Ranjan; Sinha, Sanjeev; Panda, Ashutosh; Singh, Yogita; Joseph, Anju; Deb, Manorama // Korean Journal of Parasitology;Dec2015, Vol. 53 Issue 6, p705 

    Intestinal parasitic infections are one of the major causes of diarrhea in human immunodeficiency virus (HIV) seropositive individuals. Antiretroviral therapy has markedly reduced the incidence of many opportunistic infections, but parasite-related diarrhea still remains frequent and often...

  • Poor Immune Reconstitution in HIV-Infected Patients Associates with High Percentage of Regulatory CD4+ T Cells. Horta, Ana; Nobrega, Claudia; Amorim-Machado, Pedro; Coutinho-Teixeira, Vitor; Barreira-Silva, Palmira; Boavida, Susana; Costa, Patrício; Sarmento-Castro, Rui; Castro, António Gil; Correia-Neves, Margarida // PLoS ONE;Feb2013, Vol. 8 Issue 2, p1 

    CD4+ regulatory T cells (Tregs) are essential for the maintenance of the immune system's equilibrium, by dampening the activation of potential auto-reactive T cells and avoiding excessive immune activation. To correctly perform their function, Tregs must be maintained at the right proportion...

  • Evaluation of PIMA™® Point of Care Technology for CD4 T Cell Enumeration in Kenya. Mwau, Matilu; Adungo, Ferdinard; Kadima, Silvia; Njagi, Ephantus; Kirwaye, Carolyne; Abubakr, Najma Salim; Okubi, Lucy Atsieno; Waihenya, Mary; Lusike, Judi; Hungu, Jackson // PLoS ONE;Jun2013, Vol. 8 Issue 6, p1 

    CD4+ T cell enumeration is used to determine eligibility for antiretroviral therapy (ART) and to monitor the immune status of HIV-positive patients; however, many patients do not have access to this essential diagnostic test. Introducing point of care (POC) testing may improve access. We have...

  • Rate and determinants of treatment response to different antiretroviral combination strategies in subjects presenting at HIV-1 diagnosis with advanced disease.  // BMC Infectious Diseases;2011, Vol. 11 Issue 1, p341 

    The article offers information on a study conducted on treatment response to different antiretroviral combination strategies for patients with advanced disease at HIV-1 diagnosis. It states that the response rate was different and better in baseline cluster of differentiation (CD) 4+ T cell...

  • When to Begin Highly Active Antiretroviral Therapy? Evidence Supporting Initiation of Therapy at CD4 + Lymphocyte Counts <350 cells/µµ L. Kaplan, Jonathan E.; Hanson, Debra L.; Cohn, David L.; Karon, John; Buskin, Susan; Thompson, Melanie; Fleming, Patricia; Dworkin, Mark S. // Clinical Infectious Diseases;10/1/2003, Vol. 37 Issue 7, p951 

    Assesses the risk of AIDS-related opportunistic illness or death among persons first prescribed highly active antiretroviral therapy in the U.S. Increase of HIV plasma RNA levels; Improvement of the quality of life of HIV-infected persons; Cause of the decrease of CD4[sup +] lymphocyte counts.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics